★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
editor@theamericanjournals.comPublisher Home ↗
Applied Sciences OPEN ACCESS

PPARγ as a Therapeutic Target in Myositis: Current Perspectives on Repurposed Drugs and Phytochemicals

Akarshika Choubey
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India
Anika Pandey
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India
Enaya Tufail
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India
Somali Sanyal
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow-226028, India
DOI Crossref DOI 10.37547/tajas/warm-12
tajas 2026
JOURNAL PUBLICATION MAY
FULL TEXT PP. 107-112
DOWNLOAD PDF

View all articles in this issue ↗

VOLUME —
ISSUE —
YEAR 2026
PAGES 107-112
RESEARCH OVERVIEW

Abstract

Myositis refers to a cluster of rare chronic autoimmune disorders defined by muscle inflammation and progressive weakness. Standard therapy such as corticosteroids and immunosuppressants has considerable toxicity associated with them and is frequently ineffective in controlling the disease. Peroxisome proliferator-activated receptor gamma (PPARγ), a ligand activated nuclear receptor, has been implicated in myositis as well for its function on the regulation of inflammation and metabolism. PPARγ activation inhibits inflammatory pathways including, in particular, NF-κB signaling and guides immune resolution. In this review, the mechanistic role of PPARγ in myositis is discussed and drug repurposing, a strategy to screen for well-known FDA-approved compounds with putative PPARγ-modulating activity, is considered. Moreover, the similarities between phytochemicals (in particular flavonoids) and small molecules render the former as natural ligands

RESEARCH TOPICS

Keywords

Myositis PPARγ Drug repurposing Phytochemicals.

Downloads

Download data is not yet available.
SOURCES & SCHOLARSHIP

References

  1. Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3(8), 673–683. https://doi.org/10.1038/nrd1468
  2. Aggarwal, R., & Oddis, C. V. (2011). Therapeutic advances in myositis. Current Opinion in Rheumatology, 23(6), 635–641.
  3. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
  4. Dalakas, M. C. (2015). Inflammatory muscle diseases. The New England Journal of Medicine, 372(18), 1734–1747. https://doi.org/10.1056/NEJMra1402225
  5. Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004). PPARs and the complex journey to obesity. Nature Medicine, 10(4), 355–361. https://doi.org/10.1038/nm1025
  6. Leyva-López, N., Gutierrez-Grijalva, E., Ambriz-Pérez, D., & Heredia, J. (2016). Flavonoids as cytokine modulators: A possible therapy for inflammation-related diseases. International Journal of Molecular Sciences, 17(6), 921. DOI: 10.3390/ijms17060921
  7. Liu, Y., Wang, J., Luo, S., Zhan, Y., & Lu, Q. (2020). The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review. Journal of Autoimmunity, 113, 102510. https://doi.org/10.1016/j.jaut.2020.102510
  8. Mammen, A. L. (2010). Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Annals of the New York Academy of Sciences, 1184(1), 134–153. https://doi.org/10.1111/j.1749-6632.2009.05119.x
  9. Manickam, R., Duszka, K., & Wahli, W. (2020). PPARs and Microbiota in Skeletal Muscle Health and Wasting. International journal of molecular sciences, 21(21), 8056. https://doi.org/10.3390/ijms21218056
  10. Mishra, A. S., Vasanthan, M., & Malliappan, S. P. (2024). Drug Repurposing: A Leading Strategy for New Threats and Targets. ACS pharmacology & translational science, 7(4), 915–932. https://doi.org/10.1021/acsptsci.3c00361
  11. Needham, M., & Mastaglia, F. L. (2007). Inclusion body myositis: Current pathogenetic concepts and diagnostic and therapeutic approaches. The Lancet Neurology, 6(7), 620–631. https://doi.org/10.1016/S1474-4422(07)70171-0
  12. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine, 356(24), 2457–2471. https://doi.org/10.1056/NEJMoa072761
  13. Nosengo, N. (2016). Can you teach old drugs new tricks? Nature, 534(7607), 314–316. https://doi.org/10.1038/534314a
  14. Oddis, C. V., & Aggarwal, R. (2018). Update on the pharmacological treatment of adult myositis. Nature Reviews Rheumatology, 14(5), 279–289. https://doi.org/10.1038/nrrheum.2018.33
  15. Pushpakom, S., et al. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
  16. Raquel, M., João F., & Pedro M. (2025). Treatment of idiopathic inflammatory myopathies. Joint Bone Spine, 92(6), 105932. https://doi.org/10.1016/j.jbspin.2025.105932
  17. Renato Mantegazza & Paolo Bernasconi. (2013). Inflammatory myopathies: Dermatomyositis, polymyositis and inclusion body myositis. In Madame Curie Bioscience Database [Internet]. Landes Bioscience. NCBI Bookshelf
  18. Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014). Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metabolism, 20(4), 573–591. https://doi.org/10.1016/j.cmet.2014.08.005
  19. Straus, D., & Glass, C. (2007). Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends in Immunology, 28(12), 551–558. https://doi.org/10.1016/j.it.2007.09.003
CONTINUE EXPLORING

Most read articles by the same author(s)

Explore other published research by the authors of this article.